The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
本发明涉及Formula (I)的某些取代的反向
吲唑化合物及其药学上可接受的盐,其中R1A、R1B、X、Y、RZ和R2如本文所定义,这些化合物是LRRK2激酶的强效
抑制剂,并且在治疗或预防LRRK2激酶参与的疾病,如帕
金森病和本文所述的其他疾病和疾病中有用。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗LRRK-2激酶参与的这类疾病中使用这些化合物和组合物。